CONFIDENTIAL  A Phase Ill Multicenter , Randomized , Double -blind , 
Placebo-controlled Study to Determine  Efficacy and Safety 
of BXCL501 in Agitation Associated with Bipolar Dosorder  
NCT042 76883  
01/31/202 0 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 4 of 59 
 2. INVESTIGATOR AGREEMENT 
 
PROTOCOL TITLE:  A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 
PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY 
AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH 
BIPOLAR DISORDER    
 
 
PROTOCOL NUMBER:  BXCL501-302 
 I have read the protocol and agree that it, along with the rela ted Clinical Trial Agreement, 
contains all the details necessa ry to carry out the study. I will conduct this study according to the 
protocol and will complete the st udy in the time agreed. Potential additions or modifications to 
the study will be by mutual written agreement be tween BioXcel Therapeutics, Inc. and me and 
will be documented and filed, if required, with  the Institutional Review Board and the United 
States Food and Drug Administration.  I will provide copies of the protocol and other pe rtinent information to all individuals responsible 
for assisting me in the study.  BioXcel Therapeutics, Inc., Cognitive Research  Corporation, and their designees will have 
access to source documentation from which case reports have been generated.   
Investigator Signature: _________________________________   Date:  ___________________ 
 
Investigator Name (print):  ___________________________________________________________  
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 10 of 59 
 Table 3.1:  Schedule of Events 
   Treatment Evaluation Day 1  
Activity 
Screening Pre-
Dose1  
Post Dose Time1 Day 2 
Follow-Up 
(+1) Day 3 
Discharge  Day 7 
(+2) 
Time point Pre-
treatment -1 hr to 
time 0 10 
min 20 
min 30 
min 45 
min 1 
hr 1.5 
hr 2 
hr 4 
hr 6 
hr 8 
hr 24 hr 
(-9/+12 hr)  End of 
Study 
Informed Consent X               
Medical History X               
Demographics X               
Weight X            X   
Height X               
B M I  X                
Alcohol Breathalyzer X               
MINI X               
Physical Exam X            X   
Safety Labs2 X              X X 
ECG with rhythm strip  3  X X        X     X   
Pulse oximetry  X   X  X  X X  X    
Resting vital signs4 X X   X  X  X X X X X X X 
Orthostatic vital signs4 X X       X X  X X X X 
Admit to Unit X               
Inclusion/Exclusion 
criteria X X              
Randomization  X              
Study drug administration
9  X               
YMRS  X           X   
PCRS5 X X       X    X   
PEC5 X X X X X X X X X X X X X   
ACES5  X       X X  X    
CGI-Severity6 X X              
CGI-Improvement6     X  X  X X      
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 11 of 59 
    Treatment Evaluation Day 1  
Activity 
Screening Pre-
Dose1  
Post Dose Time1 Day 2 
Follow-Up 
(+1) Day 3 
Discharge  Day 7 
(+2) 
Time point Pre-
treatment -1 hr to 
time 0 10 
min 20 
min 30 
min 45 
min 1 
hr 1.5 
hr 2 
hr 4 
hr 6 
hr 8 
hr 24 hr 
(-9/+12 hr)  End of 
Study 
C-SSRS X X           X X  
Buccal (SL) assessment 
for local irritation7     X    X X   X   
Likert Scales    X            
Likability Questions    X            
Pharmacokinetic Sampling
8       X   X   
X 
    
Concomitant Meds X X X X X X 
Adverse Events X X X X X X 
 
Notes to the Schedule of Events: 
1 Pre-dose assessments will have a window of 60 minutes prior to dose with the exception of PEC and ACES which will be performed  within 15 minutes of 
dosing (15 to 0 min). All post-dose assessments will have a window of -5/+15 minutes through the 1.5 hour assessments, -5/+25 m inutes for the 2 hour 
assessments (with the exception of the PEC which will have a +/-5  minute window) and ± 30 minutes for the 4, 6 and 8 hour asses sments and YMRS can be 
performed at any time. 
2 Safety Labs will include chemistry, hematology, urinalysis, UD S (local lab, only conducted at screening), alcohol breathalyzer  (only conducted at screening), 
and urine pregnancy (only conducted at screening). Screening/enrollment labs: local labs drawn within 7 days prior to screening  may suffice with the exception 
of urine drug screen. If results not available on the same day, a ‘desktop’ or non-CLIA test may be performed; to confirm, resu lts from a CLIA-certified 
laboratory should be recorded once available. Central La bs should be performed on Screening, Day 3 and Day 7. 
3 ECG for pre-dose does not need to be repeated if screening ECG is conducted on the day of dosing. ECGs collected following tre atment are to be performed 
prior to PK assessments. 
4 Resting (recumbent) vital signs (SBP, DBP and HR) will be taken upon having the subject recumbent for 5 min at Screening, Pre- dose and at 30 min, 1, 2, 4, 6, 
8 and 24 hours post dose, as well as Day 3 and Day 7. Triplicate m easurements to be performed in case of Systolic BP <90 mmHg, Diastolic BP <60 mmHg or 
Pulse < 60 bpm. Orthostatic measur ements (SBP, DBP, HR, respirator y rate) will be taken upon having the subject stand, with mea surements taken after 1,3 and 
5 minutes and temperature will be taken at Screening, Pre-dose, 2, 4, 8 and 24 hours post first dose, as well as Day 3 and Day 7.  
5 PEC will be performed at Screenin g, Pre-dose (within 15 min prior to dose) and at 10, 20, 30, 45 min; 1, 1.5, 2, 4, 6, 8 and 2 4 hours post dose. The PCRS must 
be performed prior to PEC rating, when requi red. ACES will be performed at Pre-dose (w ithin 15 min of dose), 2, 4 and 8 hrs pos t dose. 
6 CGI-Severity will be performed at Screen ing and pre-dose. CGI-Improvement will be pe rformed at 30 minutes, 1, 2 and 4 hours po st dose. 
7 Buccal exam at 30 min, 2, 4 and 24hr post-dose for local irritation.  
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 12 of 59 
 8 PK blood samples will be collected 1, 4, and 8 hr (while awake) after dose. A sample may not be collected if the Physician ind icates in source documents that 
the patient is in a mental state that is not conducive to PK sa mple collection. Non-compliance or refusal of all or any PK draw  will not be exclusionary nor result 
in ET. Vital signs are to be done prior to PK samp le draws, when performed at the same timepoints.  
9 The investigator may choose to re-dose the patient after the 2 hour post-dose assessments are performed if the PEC change from baseline is < 40%. Patients can 
be re-dosed after completing the 2 hour post first dose assessments. Repeat dosing administers half of a film. Patients can be redosed twice in the 12 hour period 
post first dose . All assessments listed in this Schedule of Events at the 2 hour post first dose timepoint should be repeated at 2 hours post every re-dose. 
Assessments at 4, 6, or 8 hour post first dose that occur within 1 hour of a post re-dose assessment are not required to be per formed.
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 13 of 59 
 4. TABLE OF CONTENTS 
 
1. PROCEDURES IN CASE OF EMERGENCY ............................................................3  
2. INVESTIGATOR AGREEMENT ...............................................................................4  
3. SYNOPSIS ...................................................................................................................5  
4. TABLE OF CONTENTS ...........................................................................................13  
4.1 List of Tables .....................................................................................................16  
5. LIST OF ABBREVIATIONS A ND DEFINTIONS OF TERMS ..............................17  
6. INTRODUCTION ......................................................................................................20  
6.1 Background and Rationale ................................................................................20  
6.2 Description ........................................................................................................22  
7. OBJECTIVES .............................................................................................................23  
7.1 Primary Endpoint ..............................................................................................23  
8. STUDY DESIGN .......................................................................................................24  
8.1 Overall Study Design and Plan .........................................................................24  
8.2 Discussion of Study Design ..............................................................................24  
8.3 Study Sites .........................................................................................................25  
9. SUBJECT POPULATION .........................................................................................26  
9.1 Selection of Study Population ...........................................................................26  
9.2 Inclusion Criteria ...............................................................................................26  
9.3 Exclusion Criteria ..............................................................................................26  
9.4 Removal of Subjects from Therapy or Assessment ..........................................27  
10. STUDY TREATMENTS ............................................................................................28  
10.1 Method of Assigning Subjects to Treatment Groups ........................................28  
10.2 Identification of Investigational Product ...........................................................28  
10.3 Treatment Administration .................................................................................28  
10.4 Storage ...............................................................................................................28  
10.5 Labeling .............................................................................................................28  
10.6 Drug Accountability ..........................................................................................28  
10.7 Blinding and Unblinding Treatment Assignment .............................................29  
10.8 Treatment Compliance ......................................................................................29  
10.9 Concomitant Medications ..................................................................................29  
Permitted Therapies ..........................................................................................29  
Prohibited Therapies .........................................................................................30  
11. STUDY PROCEDURES ............................................................................................31  
11.1 Screening ...........................................................................................................31  
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 14 of 59 
 11.2 Day 1, Pre-Dose ................................................................................................31  
11.3 Day 1, Post-Dose Assessments .........................................................................32  
11.4 Day 2 (+1), Follow Up ......................................................................................33  
11.5 Day 3, Discharge ...............................................................................................33  
11.6 Day 7 (+2) .........................................................................................................34  
12. STUDY ASSESSMENTS ..........................................................................................35  
12.1 Efficacy .............................................................................................................35  
PANSS – Excitatory Component (PEC) ...........................................................35  
Agitation-Calmness Evaluation Scale (ACES) .................................................35  
CGI-S and CGI-I ...............................................................................................35  
Young Mania Rating Scale (YMRS) ................................................................36  
Placebo-Control Reminder Script (PCRS) ........................................................36  
Likert scales ......................................................................................................36  
12.2 Pharmacokinetics ...............................................................................................37  
Sample Collection & Processing .......................................................................37  
Sample Storage .................................................................................................37  
Sample Shipment ..............................................................................................37  
Analytical Procedures .......................................................................................38  
12.2.1.1 Bioanalytical Sample Analyses .................................................38  
12.2.1.2 Bioanalytical Methodology .......................................................38  
12.3 Safety .................................................................................................................38  
Adverse Events .................................................................................................39  
12.3.1.1 Adverse Event Definitions ........................................................39  
12.3.1.2 Eliciting and Document ing Adverse Events .............................40  
12.3.1.3 Reporting Adverse Events.........................................................40  
12.3.1.4 Follow-up of Adverse Events....................................................42  
C-SSRS .............................................................................................................42  
Laboratory Safety Assessments ........................................................................43  
Vital Signs .........................................................................................................43  
Electrocardiogram .............................................................................................44  
Pulse Oximetry ..................................................................................................44  
Physical Examination ........................................................................................44  
Concomitant Medications .................................................................................44  
Likert scales ......................................................................................................44  
Drug likability ...................................................................................................45  
13. STATISTICAL METHODS .......................................................................................46  
13.1 General Considerations .....................................................................................46  
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 15 of 59 
 13.2 Analysis Populations .........................................................................................46  
13.3 Statistical Analyses ............................................................................................46  
Subject Disposition and Dem ographic Characteristics .....................................46  
Efficacy Analyses .............................................................................................46  
Safety Analyses .................................................................................................48  
Pharmacokinetic Analyses ................................................................................48  
13.4 Sample Size Determination ...............................................................................49  
14. STUDY CONDUCT ...................................................................................................50  
14.1 Sponsor and Investigator Responsibilities ........................................................50  
Sponsor Responsibilities ...................................................................................50  
Investigator Responsibilities .............................................................................50  
14.2 Site Initiation .....................................................................................................50  
14.3 Study Documents ..............................................................................................51  
Good Clinical Practice Documents ...................................................................51  
Case Report Forms ............................................................................................51  
Source Documents ............................................................................................52  
14.4 Data Quality Control .........................................................................................52  
Monitoring Procedures ......................................................................................52  
Data Management .............................................................................................53  
Quality Assurance/Audit ...................................................................................53  
14.5 Study Termination .............................................................................................53  
Regular Study Termination ...............................................................................53  
Premature Study Termination ...........................................................................53  
14.6 Study Site Closure .............................................................................................54  
Record Retention ...............................................................................................54  
Sample Retention ..............................................................................................54  
14.7 Changes to the Protocol .....................................................................................55  
14.8 Use of Information ............................................................................................55  
15. FINAL CLINICAL STUDY REPORT ......................................................................56  
16. ETHICAL AND LEGAL CONSIDERATIONS ........................................................57  
16.1 Declaration of Helsinki a nd Good Clinical Practice .........................................57  
16.2 Subject Information and Informed Consent ......................................................57  
16.3 Approval by Institutional Review Board ...........................................................57  
17. REFERENCES ...........................................................................................................58  
 
 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 16 of 59 
 4.1 List of Tables 
Table 1.1:   Sponsor/CRO Contact Information .........................................................3  
Table 3.1:   Schedule of Events ................................................................................10  
Table 13.1:   Estimated Sample Size group for power of 0.90 ...................................49  
Table 13.2:   Estimated Sample Size group for power of 0.85 ...................................49  
 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 17 of 59 
 5. LIST OF ABBREVIATIONS AN D DEFINTIONS OF TERMS 
Abbreviation Definition 
ACES A gitation-Calmness Evaluation Scale 
AE Adverse event 
ANCOVA Anal ysis of covariance 
API Active Pharmaceutical In gredient 
AUC Area under the plasma c oncentration vs time curve 
BP Blood pressure 
BMI Bod y Mass Index 
C Celsius/Centi grade 
CGI-I Clinical Global Impression-Improvement 
CGI-S Clinical Global Impression-Severit y 
CLIA Clinical Laborator y Improvement Amendments 
Cmax Maximum plasma concentratio n 
CNS Central nervous s ystem 
CRF Case Report Form 
CRO Contract Research Or ganizatio n 
CSR Clinical Study Report 
C-SSRS Columbi a-Suicide Severit y Ratin g Scale 
CTCAE Common Terminolo gy Criteria for Adverse Events 
DBP Diastolic blood pressure 
Dex or DEX Dexmedetomidine 
DLT Dose Limitin g Toxicit y 
DSM Dia gnostic and Statistical Manua l of Mental Disorders 
ECG Electrocardio gram 
EDTA Eth ylenediaminetetraacetic aci d 
ET Earl y Terminatio n 
FDA US Food and Dru g Administratio n 
FD&C United States Federal Food, Dru g, and Cosmetic Act 
g gram 
GABA Gamma-Amino Butyric Aci d 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 18 of 59 
 Abbreviation Definition 
GCP Good Clinic al Practices 
HCl H ydrochloride 
HR Heart rate 
hr hou r 
ICH International Conference on Harmonisatio n 
ICU Intensive Care Unit 
IM Intramuscula r 
IRB Institutional Review Boar d 
ITT Intent To Treat 
IUD Intrauterine Device 
IV  Intravenous 
kg kilo gram 
LC/MS/MS Liquid chromato graphy-tandem mass spectrometr y 
LD Listed Drug 
LOCF Last Observation Carried Forwar d 
MedDRA Medical Dictionar y for Re gulator y Activities 
mg milli gram 
MHRA Medicines and Healthcare products Re gulator y Agency 
Min Minutes 
mL millilite r 
mm millimeters 
mmHG millimeters of mercur y 
MMRM Mixed model repeated measures 
MS Mass spectrometr y 
MTD Maximum tolerated dose 
MW Molecular weight 
PANSS-EC Positive and Ne gative S yndrome Scale – Excited Component 
PCRS Placebo-Control Reminder Script 
PD Pharmacod ynamics 
PEC Positive and Negative S yndrome Scale – Excited Component 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 19 of 59 
 Abbreviation Definition 
pg pico gram 
pH measure of hydrogen ion concentration 
PI Principal Investi gator 
PK Pharmacokinetic 
po oral/b y mouth 
POC Proof of Concept 
PP Per Protocol 
RASS Ramsa y Sedation Scale 
SAE Serious adverse event 
SAP Statistical Anal ysis Pla n 
SBP S ystolic blood pressure 
SL Sublin gual  
THC Tetrah ydrocannabinol 
Tmax Time that dru g is present at the maximum concentration in serum 
µg/µcg Micro gram 
UDS Urine Drug Scree n 
USP United States Pharmacopeia  
YMRS Youn g Mania Ratin g Scale 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 20 of 59 
 6. INTRODUCTION 
6.1 Background and Rationale 
Background 
Agitation is a severe, disruptive, and morbid co mplication of many chronic mental illnesses, 
including schizophrenia (Osser and Sigadel 2001), dementia (C onn and Lieff 2001), and bipolar 
disorder (Alderfer and Allen 2003 ). Currently, the standard of care in the treatment of acute 
agitation is pharmacological tranquilization with an tipsychotics (either typical or atypical) and/or 
benzodiazepines (Currier and Trenton 2002; Currier  et al. 2004; Battaglia  2005). These drugs are 
available in a variety of forms, including oral tablets, orally di sintegrating tablets, oral liquids, 
and intramuscular injections (IM). Efficacy has b een demonstrated for each of these agents, but 
onset of action after both oral and intramuscular administration is typically 30-60 min due to 
slow absorption into the systemic  circulation. Slow onset of acti on extends suffering of agitated 
patients and increases the need for physical restraint or secl usion (Allen et al. 2003).  
In contrast to oral or  IM administration, intrav enous injection (IV) results in onset of anti-
agitation action within 1-5 min (Allen et al. 2001, 2003). However, it is generally impractical to 
use IV administration in agitated patients. According to expert consensus guidelines developed 
by 50 leading US experts in behavioral emergencie s (Allen et al. 2001), speed of onset of anti-
agitation effects was viewed as the most important  factor in selecting an agitation treatment. The 
discrepancy between the need for speed of onset in trea tment of agitation a nd the slow onset of 
most frequently utilized treatme nts represents a substantial unme t medical need in the population 
of patients with behavioral emergencies. An alternative non-invasive yet rapidly delivered 
medication which produces a rapid ca lming effect that allows patients to participate in their care 
and treatment would find use in the pharmacol ogical management of  acute agitation.  
BioXcel Therapeutics Inc. is developing a s ublingual film formulati on of dexmedetomidine 
(BXCL501) for the acute treatment of hyper-arous al in agitated patient s with schizophrenia, 
bipolar disorder, and dementia. Dexm edetomidine is a highly selective α2 adrenoceptor agonist 
on presynaptic neurons. The stimulation of these receptors in the locus coeruleus leads to a 
decrease in norepinephrine rel ease from presynaptic neurons w ith inhibition of postsynaptic 
activation, which attenuates central nervous syst em (CNS) arousal, and diminishes the fight-or-
flight response (MHRA 2014). By controlling norepinephrine release from the locus coeruleus, 
BXCL501 has a novel mode of actio n compared to current ther apies (D2 antagonists and GABA 
agonists) and is previously untes ted for the treatment of acute agitation. In addition, because it 
enters the blood stream directly by the sublingual route and bypa sses first-pass metabolism in the 
liver, dexmedetomidine from BXCL5 01 is less susceptible to varia tions in hepatic function than 
orally administered drugs. 
Dexmedetomidine is currently approved in the United States (US) as the intravenous injectable 
formulation, Precedex® (Precedex US Package Insert, 2016), for acute procedural and ICU 
sedation. Dexmedetomidine has been  administered by the oral, nasal,  and oral mucosal routes in 
both nonclinical and clinical  studies with substan tial bioavailability via the oral mucosal route 
and no route-specific safety signals (oral mucosal or gast rointestinal).  
BXCL501 is a sublingual thin film formulation of dexmedetomidine which is intended for the 
acute treatment of agitation. BXCL501 is design ed as a self-administere d discrete low dose film 
with mucoadhesive properties. It is therefore expected that its administration in agitated patients 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 21 of 59 
 will lead to faster onset of clinical response than administration of oral or intramuscular 
preparations.  
BXCL501 was evaluated for PK, bioavailability  and safety in a randomized, double-blind, 
placebo-controlled trial. Doses from 10 to 40 µg (Study BXCL501-101) in healthy volunteers 
produced lower systemic exposure (Cmax and AUCs)  compared to the PK parameters presented 
in the Precedex package insert and was safe an d well tolerated. Sedation as measured by visual 
analog scale and other measures were similar for BXCL501 in cont rast with placebo at each dose 
level; while there was a greater incidence of arousable sedation for the highest dose tested. 
Cardiovascular activity was monito red with relatively few incide nts of bradycardia, hypotension 
or orthostatic hypotension that were either non -reproducible or generally mild and transient.  
A multicenter, double-blind, placebo-controlle d, Phase 1b trial (Study BXCL501) was conducted 
in agitated subjects with schizophrenia to evaluate the safety and efficacy BXCL501. Subject self-administration of BXCL501, with doses rang ing from 20 to 180µg, was associated with a 
safe, well-tolerated and effec tive calming as measured by a reduction in PEC scores at 2 hours. 
Preliminary results of the BXCL501-102 study suggested calming effects as measured by group mean reduction from baseline PEC score achieving statistically signifi cant separation from 
placebo as early as 45 min, at 2 hr and maintain ed through 6 hrs and longer. There were no SAEs 
and treatment-emergent AEs were generally transient, mild to moderate in severity. The most commonly reported AEs were arousable, intermittent somnolence (of mild to  moderate severity) 
and dry mouth. There were no clinically meaningful  changes in cardiovascular parameters in the 
180µg dose group and no medical interventions were necessary.  
Agitation can be seen in different bipolar disorders but is predomin antly associated with bipolar I 
disorder and is less frequently observed in bipo lar II disorder. This study will enroll subjects with 
agitation associated with bipolar  I or II disorder. Bipolar diso rder, as defined by DSM-5, is 
subdivided into distinct disord ers, the most common being bipol ar I disorder, or bipolar II 
disorder. Bipolar I disorder is associated with at least one full episod e of mania and possible 
additional episodes of full depressi on, occurring later in time or c oncurrently (“mixed episodes”). 
Bipolar II disorder is characteri zed by at least one episode of hypomania and at least one episode 
of major depression. Episodes in bipolar I and II disorders may be recurrent and progress in 
severity over time.  As noted previously, agitation is a common occu rrence in multiple psyc hiatric disorders, and 
while the etiology of agitation is not fully understood, hypothesized dysfunctions in 
norepinephrine, dopamine, serotonin and GABA syst ems are consistent with the demonstrated 
efficacy of agents such as benzodiazepines and typical and atypical antipsychotics 
(Lindenmayer, 2000; Battag lia 2005; Berk 2005). In recent year s, formulations of the atypical 
antipsychotics Zyprexa (Meehan, 2001), Geodon (B ellnier, 2002), and Ab ilify (Sanford, 2008) 
for intramuscular injection have  received FDA approval for treati ng agitation in patients with 
bipolar I disorder with mania or mixed episodes (w ith or without psychotic features), as well as 
approval for treating agitation in  patients with schizophrenia. The schizophrenia and bipolar 
disorder studies have generally utilized similar clin ical trial designs to ev aluate the efficacy and 
safety of these agents over a 24 hour period fo llowing intramuscular injection. Furthermore, for 
each agent, similar effi cacious dose ranges were approved fo r treating agitation in bipolar 
disorder and schizophrenia.  
 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 22 of 59 
 Study Rationale 
The purpose of the present Phase 3 study is to a ssess the safety and efficacy of BXCL501 in the 
treatment of acute agitati on in patients with bipolar I or II disorder with hypomania, mania or 
mixed episodes and to assess the safety and to lerability over a 24-hour period. The study will be 
conducted in patients who are either newly admitte d to a hospital setting or a research unit for 
acute agitation, or al ready in-hospital for the tr eatment of bipolar disord er. Patients meeting entry 
criteria will be randomized to 180µg BXCL501 or 120 µg BXCL501 or to matching placebo. 
Following administration of study drug, assessment of agitation will be conduc ted at serial time 
points using standard agitati on scales over a 24-hour period. The PANSS Excited Component 
(PEC) scale will be the pr imary efficacy measure. 
6.2 Description 
Dexmedetomidine hydrochloride is the active S-enantiomer of  medetomidine. BXCL501 is a 
sublingual film comprised of dexmedetomidine and the follo wing inactive ingredients: 
Polyethylene Oxide, Hydroxypropyl Cellulose, Su cralose, Peppermint Oil, Emerald Green 
colorant, and FD&C Blue #1 colorant. 
No special transport or storage conditions ar e required for BXCL501. P ackaged films can be 
stored at room temperature (25°C) and ambient humidity. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 23 of 59 
 7. OBJECTIVES 
7.1 Primary Endpoint 
The primary efficacy endpoint of the study will be the absolute change from baseline in the PEC 
total score at 2 hours. The intent  to treat population will be analyz ed and consists of all patients 
who take any study medication and who had both baseline and at least 1 efficacy assessment 
after dosing. Observations record ed after use of rescue medication will be censored (considered 
missing).   
7.2 Key Secondary Endpoint: 
The key secondary efficacy endpoint will be the earliest time where an effect on agitation is 
apparent as measured by cha nge from baseline PEC total score in contrast with placebo.  
Exploratory endpoints include: 
1. Overall clinical improvement  after drug administration as  measured by the Clinical 
Global Impression – Improvement Scale (CGI-I) score. 
2. Agitation-Calmness Evaluation Scale (ACES) scores at 2, 4 and 8 hrs after dose 
administration.  
3. Change from baseline in total PEC score over time measured from 10 min through 24 
hrs after dosing.  
4. PEC Responders and CGI-I Responders at 2 hours following dose of BXCL501, compared with placebo:   
a. PEC responders will be defined as those who achieve at least a 40% reduction in 
PEC total score from baseline at or before 2 hours post-dose. 
b. CGI-I responders will be defined as subj ects with a score of 1 or 2 on the CGI-I 
scale (the CGI-I non-responders will be define d as subjects with scores from 3 to 
7 at 2 hours).   
5. Time to rescue medication dur ing the entire 24 hrs Post-treatment Evaluation Period for 
subjects receiving BXCL501 compared to placebo. 
6. Proportion of subjects per treatment group w ho received rescue me dication by 4 hrs and 
within 24 hrs after dosing.  
7. Duration of calming effect as described by the change from baseline in PEC total score, 
and ACES score at 2, 4 and 8 hrs after dosing. 
8. Determine the safety profile of BXCL501 as  measured by vital signs and treatment-
emergent adverse event reports.  
9. Describe the overall tolerability in term s of adverse event re ports and local site 
(oral/sublingual) tolerability of oral film. 
10. Descriptive pharmacokinetics of BX CL501 in the patient population. 
11. Determine patient acceptability, taste and likability of study me dication using likert 
scales to capture subject’ s acceptability, opinion on taste and questions regarding 
likability. 
12. Characterize the patient population utiliz ing the Young Mania Rating Scale (YMRS). 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 24 of 59 
 8. STUDY DESIGN 
8.1 Overall Study Design and Plan 
The study will enroll approximately 375 subjects  randomized 1:1:1 to dose regimens of 180µg, 
120µg BXCL501, or placebo stratified by age < 65 and age ≥ 65. The doses were selected based 
on the results of the prior Phase Ib  clinical trial (Study BXCL501-102).  
Male and female adults with acute agitation asso ciated with bipolar I or  II disorder will be 
enrolled.  
Eligible subjects (acutely agitated subjects with bi polar I or II disorder) may be identified in 
outpatient clinics, mental health, psychiatri c or medical emergenc y services including 
medical/psychiatric observati on units, or as newly admitted to a hospital setting for acute 
agitation or already in hospital for chronic unde rlying conditions. Subjects will be domiciled in a 
clinical research sett ing or hospitalized to remain under medical supervision while undergoing 
screening procedures to assess eligibility. Upon confirmation of eligibility, subjects will be randomized to 180µg BXCL501 or 120
µg 
BXCL501 or matching placebo.  Efficacy and safety assessments will be conducted periodically 
before and after dosing.  Vital Signs, pulse oximetry and ECG with rhythm stri p will be measured as per schedule of 
assessments, prior to any PK assessments. Par ticipants will be allowed water as desired 15 
minutes after completion of dosing. Safety and tolerability assessments will be conducted  at 
various timepoints. Please refer to the Table 3.1 Schedule of events for details. 
Any abnormal vital sign measuremen t, clinical laboratory test, physical examination finding, or 
ECG parameter deemed clinically significant by the investigator wi ll be repeated, including test 
results obtained on the final study day or upon early termination. For any test abnormality 
deemed clinically significant, repeat analysis will be perform ed during the follow-up period and 
until the value returns to baseline (or within  normal limits) or the investigator deems the 
abnormality to be stable and no l onger of clinical  concern.    
Approximately 4 mL of venous blood (to obtain a minimum of 1.2 mL plasma ) will be taken into 
K2-EDTA tubes at set time intervals for the dete rmination of plasma concentrations of study 
drug (or Placebo). The PK plasma samples should  be collected within 10 min of the scheduled 
sampling time on Day 1. Blood samples will be coll ected per Table 3-1 Schedule of Events.  
8.2 Discussion of Study Design 
This is a definitive study to support the safety  and efficacy evaluation of BXCL501 for the acute 
treatment of agitation in bipolar  disorder.  The BXCL501-302 study is designed to characterize 
the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in 
agitation associated with bipolar disorder. A dos e of BXCL501 was chosen based on results from 
BXCL501-102 that showed rapid efficacy in a la rge proportion of subjects, was well tolerated 
and had an acceptable safety profile.  In th e event of persistent or recurrent agitation, 
investigators may choose to repeat dose at 90µg or 60µg (half of 180µg or 120µg  film) after the 
2-hour time point as measured by a PEC change from baseline <40% but in the absence of safety 
concerns. Patients can only be re-dosed if they are hemodynamically stable, not hypotensive 
(must be greater than 90/60 systolic/diastolic) and not bradycardic (mus t be greater than 60 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 25 of 59 
 bpm). Patients also cannot be re-dosed if they are  orthostatic ( a drop of > 20 mm Hg systolic, or 10 
mm Hg diastolic  ) or if they are experiencing an AE that  in the assessment of the PI precludes 
redosing.. The maximum number of repeat doses per subject is 2, during the 12 hours post first 
dose. Doses may not be adminis tered sooner than 2 hours after a previous dose. If the PEC 
change from baseline is >40%  repeat dosing is not allowed. 
Placebo was chosen as a comparator to more accu rately assess efficacy as well as safety and 
tolerability.  The randomized, double blind pa rallel-group design ensures the sponsor, all 
subjects, and study staff involved are shielded  from treatment assignment and outcomes and 
therefore will minimize any potential bias. Th e randomization ratio pr ovides an additional 
element to ensure blinding by decreasing the odd s of guessing treatment  arms.        
8.3 Study Sites 
The study will take place at up to 30 sites in the US.  
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 26 of 59 
 9. SUBJECT POPULATION 
9.1 Selection  of Study  Population 
9.2 Inclusion Criteria 
A subject will be eligible for inclusion in the study if he or she meets the following criteria: 
1. Male and female patients between the ages of 18 to 75 years, inclusive. 
2. Patients who have met DSM-5 criteria for bipolar I or II disorder. 
3. Patients who are judged to be clinically agitated at Screening and Baseline with a total 
score of ≥ 14 on the 5 items (poor impulse contro l, tension, hostility, uncooperativeness, 
and excitement) comprising the P ANSS Excited Component (PEC). 
4. Patients who have a score of ≥ 4 on at least 1 of the 5 items on the PEC at Baseline . 
5. Patients who read, understand, and provi de written informed consent. 
6. Patients who are in good general health prio r to study participation as determined by a 
detailed medical history, physical examin ation, 12-lead ECG with rhythm strip, blood 
chemistry profile, hematology, urinalysis, and in the opinion of the Principal Investigator. 
7. Female participants, if of child-bearing potential and sexually active, and male 
participants, if sexually active with a partne r of child-bearing potential, who agree to use 
a medically acceptable and e ffective birth control method throughout the study and for 
one week following the end of the study. Medically acceptabl e methods of contraception 
that may be used by the partic ipant and/or his/her partner in clude abstinence, birth control 
pills or patches, diaphragm with spermici de, intrauterine device (IUD), condom with 
foam or spermicide, vaginal spermicidal suppository, surgical sterilization, and progestin 
implant or injection. Prohibited methods include: the rhythm  method, withdrawal, 
condoms alone, or diaphragm alone. 
9.3 Exclusion Criteria 
A subject will be excluded fro m the study if he or she me ets the following criteria: 
1. Patients with agitation caused by acute int oxication, including positive identification of 
alcohol by breathalyzer or dr ugs of abuse (with the excep tion of THC) during urine 
screening.  
2. Use of benzodiazepines, other hypnotics or antipsychotic drugs in the 4 hours before 
study treatment.  
3. Treatment with alpha-1 noradrenergic bl ockers (terazosin, doxazosin, tamsulosin, 
alfuzosin, or prazosin) or other prohibited medications. 
4. Patients judged to be at serious ri sk of suicide must be excluded.  
5. Female patients who have a positive pregnancy test at screening or are breastfeeding. 
6. Patients who have hydrocephalus, seizure disord er, or history of significant head trauma, 
stroke, transient ischemic attack, subarac hnoid bleeding, brain tu mor, encephalopathy, 
meningitis, Parkinson’s disease or  focal neurolog ical findings. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 27 of 59 
 7. History of syncope or other syncopal a ttacks, current evidence of hypovolemia, 
orthostatic hypotension (avera ge of 1, 3 and 5 min measurements), a screening and 
baseline heart rate of < 55 beats per minut es or systolic blood pressure <110 mmHg or 
diastolic BP <70 mmHg. 
8. Patients with laboratory or EC G abnormalities considered clinically sign ificant by the 
investigator or qualified designee [Advanced heart bloc k (second-degree or above 
atrioventricular block without pacemaker), diagnosis of Sick  sinus syndrome] that would 
have clinical implications for the pa tient's participation in the study.  
9. Patients with serious or uns table medical illnesses. These include current hepatic 
(moderate-severe hepatic impairment), renal, gastroenterologic, respiratory, 
cardiovascular (including ischemic hear t disease, congestive heart failure), 
endocrinologic, or he matologic disease.  
10. Patients who have received an investigationa l drug within 30 days prior to the current 
agitation episode.  
11. Patients who are considered by the investig ator, for any reason, to be an unsuitable 
candidate for receiving DEX; e.g. patients with  a history of allergic  reactions to DEX. 
9.4 Removal of Subjects from Therapy or Assessment 
All subjects are free to withdraw  from participation in this st udy at any time for any reason and 
without prejudice. 
The investigator may terminate dosi ng for a subject at any time for la ck of therapeutic effect that 
is intolerable to the subject or otherwise considered unacceptable,  for intolerable or unacceptable 
AEs, intercurrent illness, nonc ompliance with study procedures , administrative reasons, or 
unsuitability for the study in the investigator’s opinion to protect the s ubject’s best interest. 
If a subject is withdrawn from dosing before comp leting the study, the reason for withdrawal will 
be entered on the appropriate case report form (CRF).  When ever possible and reasonable, 
evaluations that were scheduled for study comp letion should be perform ed at the time of 
premature discontinuation of dosing. Subjects who discontinue from the study will not be replaced.  
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 28 of 59 
 10. STUDY TREATMENTS 
10.1 Method of Assigning Subjects to Treatment Groups 
Upon confirmation of eligibility, subjects will be randomized to 180µg BXCL501 or 120µg 
BXCL501 or placebo.  
Randomization will be 1:1:1 (180µg or 120 µg BXCL501 or Placebo and stratified by age < 65, 
age ≥ 65) with 125 patients assigned to each  arm by a permuted block design. Study 
randomization will be computer generated. 
10.2 Identification of Investigational Product 
BXCL501 will be provided as a small, solid- dose film formulation, approximately 193.6 mm2 in 
area and 0.7 mm thick, designed to completely di ssolve in the SL space within 1-3 min.  
BXCL501 Sublingual Film 180µg, 120µg and placebo will  be packaged as individual films in a 
heat-sealed white foil po uch with a drug product label. The p ouch has a white colored outer layer 
with foil colored inner layer. Individual film appearance is as follows:  
 180µg – Green rectangular th in film (~22 mm x 8.8 mm)  
 120µg – Green rectangular th in film (~22 mm x 8.8 mm) 
 Placebo – Green rectangular th in film (~22 mm x 8.8 mm) 
BioXcel Therapeutics, Inc. will provide an ad equate supply of study drug to the sites. 
10.3 Treatment Administration 
At the time of dosing, patients will be instructed on how to take the investigational product 
sublingually, and that they should retain the inve stigational product in th e sublingual cavity until 
dissolved.  The patient will self-administer under th e supervision of a trained staff member. If the 
patient is unable to self-administer, the event w ill be recorded, and the subject's participation will 
conclude. 
In the event of persistent or recurrent agitation, inve stigators may choose to  re-dose at 90µg or 
60µg (cutting half of the 180µg or 120µg film) after the 2-hour ti me point as measured by a PEC 
change from baseline ≤40% but in the absence of safety concerns. 
10.4 Storage 
No special transport or storage conditions ar e required for BXCL501. P ackaged films can be 
stored at room temperature (25°C) and ambient humidity. 
10.5 Labeling 
Each pouch of study drug will be labeled with  study-specific inform ation that meets all 
applicable regulatory requirements. 10.6 Drug Accountability 
The investigator must maintain adequate records showing the rece ipt, dispensing, return, or other 
disposition of study drug, includ ing the date, quantity, batch or code number, and identification 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 29 of 59 
 of subjects (subject number and initials) who received study drug.  The investigator will not 
supply study drug to any person except those named as sub-investigators on the FDA 1572, 
designated staff, and subjects in this study.  The investigator will not dispense study drug from 
any sites other than those listed on the FDA 1572.  Study drug may not be relabeled or 
reassigned for use by other subjects. 
Upon completion of the study, unused supplie s of study drug will be reconciled by the 
investigator and returned to the sponsor or destroyed as directed. 
10.7 Blinding and Unblinding Treatment Assignment 
This study will be conducted under double-blind condi tions so that neither the subject nor the 
Investigator or study staff memb ers will know the identity of each subject’s treatment. BXCL501 
or placebo film will be provided to  the subjects for self-administration under the supervision of a 
trained staff member. Treatment assignment for an individual subject s hould be unblinded only in an emergency, when 
knowledge of the treatment assignment is urgent ly needed for the clin ical management or 
welfare of the subject. The Investigator should contact the medical mon itor or project manager 
before unblinding, when possible, but priority should be  given to treatment of the subject. If 
unblinding occurs without prior a pproval, the investigator should promptly communicate the 
circumstances leading to the unblinding by teleph one and in writing to the medical monitor. 
Breaking of the blind, other than as described abov e, will be considered a protocol violation. For 
any subject whose study drug treatment is unblinded, the da te, time, and reason for the 
unblinding must be documented. 
10.8 Treatment Compliance 
Drug accountability will be performed by site pe rsonnel and the drug administration compliance 
is expected to be 100%. 10.9 Concomitant Medications 
All concomitant medications admi nistered (including over-the-c ounter medications and herbal 
and nutritional supplements) will be  recorded in the source document and on the appropriate 
CRF. The medication name, dose, frequency, date, and indication for use must be recorded on 
the CRF.  Medications and therapies that are cons idered necessary for the subject’s welfare and 
will not interfere with the respons e to the study medication may be given at the discretion of the 
investigator. Permitted Therapies 
Concomitant medications are allowed (unless specifically prohibited) but should be limited to 
only those medications considered necessary. Smoking is allowed according to the site policies.  Rescue Medication 
At the discretion of the PI or designee, rescue therapy with lorazepam po/IM 0.5-5 mg may be 
initiated as a standard of care treatment for acute agitation.  When  rescue administration occurs, 
the time, dose and indication must be clearly recorded as ‘For  agitation’ in CRF and source 
documents.  
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 30 of 59 
 Medications for Insomnia 
Lorazepam or other benzodiazepines may be administered for insomnia. Administration may not 
occur sooner than 4 hrs after dos ing of study treatment and the indication (Insomnia) must be 
clearly recorded in CRF and source documents. 
Prohibited Therapies 
The following medications are prohibited in the 4 hours before dosi ng of study treatment:  
Sedative/hypnotics, barbiturates, anxiolytics (i ncluding benzodiazepines), antihistamines (e.g. 
diphenhydramine), sedating antidepr essants (mirtazapine, trazodone),  triptans (e.g. sumatriptan), 
opioids. The following medications are prohibited from the time of screening until 4 hours post last dose, 
unless clinically indicated: 
Antiarrhythmics, Antibiotics/antifungals/antiv irals, Anticholinergics, Anticonvulsants, 
Antipsychotics, Antihypertensive, Anxiolytics or  sedative-hypnotics, Centrally acting calcium 
antagonist, Cholinomimetics, Migraine-Ser otonin Receptor Agonist, Opioids.  
  
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 31 of 59 
 11. STUDY PROCEDURES 
Subjects will provide written informed consent be fore any study-related pr ocedures are initiated, 
including the cessation of  concomitant therapy. 
The schedule of events to be performed during the study is provided in Table 3.1. 
11.1 Screening  
Subjects must be screened a nd randomized into the study be fore dosing. When possible, 
screening and randomization will take place on the same day.  
The following procedures will be performed at Screening (refer to the Schedule of Events table): 
 Obtain written informed consent 
 Review inclusion and exclusion criteria 
 Collect demographic information 
 Record medical history, including prior and current therapies (e.g. prescription and non-
prescription medications) 
 Physical examination includi ng weight, height, body mass index, and vital signs   
 Urine pregnancy test for all fe males of childbearing potential 
 12-lead ECG with rhythm strip 
 Collect blood and urine samples for clinical  laboratory tests (h ematology, clinical 
chemistry, urinalysis, an d urine drug screen) 
 Alcohol breathalyzer 
 MINI 
 Placebo-Control Reminder Script (PCRS) (prior to PEC) 
 PEC 
 CGI-S 
 C-SSRS 
 Adverse events are recorded following informed consent 
 Record concomitant medication use 
 Admit to Clinical Research Unit (for subjects not currently admitted) 
The Screening Visit may be conducted over more th an one day; however, all procedures must be 
completed prior to subject randomization and wi thin 28 days of signing informed consent. 
Screen Failures: Subjects who fail inclusion and/or exclusion criteria may be rescreened for the 
study.  Subjects may only be rescreened one time.  
11.2 Day 1, Pre-Dose 
The following procedures will be performed prior to dosing: 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 32 of 59 
  Review inclusion and exclusion criteria 
 Assess and record AEs  
 Record concomitant medication use 
 Resting (recumbent) and Orthostatic Vital signs 
 Pulse Oximetry 
 ECG with rhythm strip (not re quired if screening ECG is conducted on the day of dosing) 
 C-SSRS 
 YMRS 
 CGI-S 
 Randomization 
 Placebo-Control Reminder Script (PCRS) (prior to PEC) 
 PEC (within 15 min of dosing) 
 ACES (within 15 min of dosing) 
Upon completion of the pre-rando mization procedures, the subject  will be randomized to study 
treatment (180µg BXCL501 or 120µg BXCL501 or placebo), study drug administration will 
occur, and the following procedures will be perfo rmed (Refer to the Schedule of Events for 
specific time points): 
11.3 Day 1, Post-Dose Assessments 
 CGI-I  
 PCRS (prior to PEC) 
 PEC 
 ACES 
 Vital Signs (Resting/Recumbent and Orthostatic) 
 ECG with rhythm strip 
 Pulse oximetry 
 Buccal (SL) Assessment 
 Likert scales 
 Likability Questions 
 Assess and record AEs 
 Record concomitant medication use 
 Plasma sample for PK analysis. A sample may not be collected if the physician in charge 
of the patient indicates in the source documents that the patient is in a mental state that is 
not conducive to PK sample collection. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 33 of 59 
 Investigators may choose to repeat dosing with  the 90µg or 60µg dose (half of 180µg or 120µg  
film) after the 2-hour time point for persistent or recurrent agit ation (PEC change from baseline 
<40%) but only in the absence of safety concer ns. Patients can only be re-dosed if they are 
hemodynamically stable, not hypotensive (must be greater than 90/60 systolic/diastolic) and not 
bradycardic (must be greater th an 60 bpm). Patients also canno t be re-dosed if they are  
orthostatic ( a drop of > 20 mm Hg systolic, or 10 mm Hg diastolic  ) or if they are experiencing an AE 
that when assessed by the PI precludes redosing. All 2 hour assessments (i ncluding efficacy and 
safety) must be completed befo re repeat dosing may occur. The maximum number of repeat 
doses allowed per subject is 2, during the 12 hours post first dose.  Doses may not be 
administered sooner than 2 hours after a previous dose. If the PEC change from baseline is >40% 
repeat dosing is not allowed. As noted in the Schedule of Events (Table 3.1 ), all assessments 
listed at the 2-hour post first dose timepoint should be repeated at 2 hours post every re-dose. 
11.4 Day 2 (+1), Follow Up 
The following procedures will be performed on Day 2: 
 ECG with rhythm strip 
 Physical exam including weight 
 Resting/Recumbent and Orthostatic Vita l sign and weight measurements   
 YMRS 
 PCRS (prior to PEC) 
 PEC  
 C-SSRS 
 Buccal (SL) Assessment  
 Record concomitant medication use 
 Assess and record AEs 
11.5 Day 3, Discharge 
The following procedures will be performed on Day 3, Discharge: 
 Collect blood and urine samples for clinical  laboratory tests (h ematology, clinical 
chemistry, and urinalysis) 
 Resting/Recumbent and Orthostatic Vital signs 
 C-SSRS 
 Record concomitant medication use 
 Assess and record AEs 
The protocol permits a maximum 3 overnight stays from allowed admission to the Clinical 
Research Unit to Discharge. If more nights are required, Medical Monitor approval is required. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 34 of 59 
 11.6 Day 7 (+2) 
The following procedures will be performed on Day 7 (+2): 
 Collect blood and urine samples for clinical laboratory tests (hematology, clinical chemistry, 
and urinalysis) 
 Resting/Recumbent and Orthostatic Vital signs 
 Record concomitant medication use 
 Assess and record AEs 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 35 of 59 
 12. STUDY ASSESSMENTS 
12.1 Efficacy 
The effect of study drug will be evaluated usi ng several validated instruments as described 
below. 
PANSS – Excitatory Component (PEC) 
Assessment of drug effect on acu te agitation will be done usin g the Positive and Negative 
Syndrome Scale – Excited Component (PEC). Th e PEC comprises 5 item s associated with 
agitation: poor impulse contro l, tension, hostility, uncooperati veness, and excitement; each 
scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscale s, thus ranges from 5 
to 35. 
Agitation-Calmness Evaluation Scale (ACES) 
The ACES is a single item measure rating ove rall agitation and sedation, where 1 indicates 
marked agitation; 2 - moderate agitation; 3 - mild agitation; 4 - normal behavior; 5 - mild 
calmness; 6 - moderate calmness; 7 - marked cal mness; 8 - deep sleep; and 9 – unarousable. 
CGI-S and CGI-I Clinical Global Impression of Severity (CGI-S) will be rated based upon the severity of agitation 
at screening and pre-dose (immediat ely prior to start of dosing). 
Severity of illness will be assessed based on following scale: 0 = Not assessed 1 = Not at all ill 2 = Borderline mentally ill 3 = Mildly ill 4 = Moderately ill 5 = Markedly ill 6 = Severely ill 
7 = Among the most ex tremely ill subjects 
Drug response on agitation will be evaluated by the Clinical Global Impressions – Improvement 
(CGI-I).  It will be performed at 30 minutes, 1, 2 and 4 hrs post dose. The CGI-I scores range 
from 1 to 7: 
0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 36 of 59 
 5=minimally worse, 
6=much worse, 7=very much worse Both CGI-I and CGI-S will be focuse d on the severity of agitation rather than the severity of the 
overall illness of bipolar disorder. 
Young Mania Rating Scale (YMRS) 
The YMRS is an 11-item scale evaluating mania symptoms base d on the patient’s subjective 
report of their clinical condition. It will be used to characterize the patient  population enrolled in 
the study. 
Placebo-Control Reminder Script (PCRS) 
The Placebo-Control Reminder Script (PCRS)
 © Hassman and Cohen, 2019, Version 5.0 educates clinical trial 
participants of key causes of th e placebo and nocebo effects, namely the tempering of participant 
study expectations, reminding subject s what a placebo is and how th at relates to their reporting 
of symptoms and potential side effects, and explaining how interactions wi th research site staff 
differ from their experience with previous providers. To do this, the PCRS informs subjects that 
they are to be honest about their symptoms, site staff have no exp ectations of symptom 
improvement or worsening and will not be disappoi nted if they feel better, worse or the same, 
and asks participants to explai n in their own words its conten t to ensure comprehension. The 
PEC Rater will read the PCRS study source before  administering the PEC to EACH subject at 
EACH Visit (time point) listed on the study specific PCRS, typical ly taking about 2 minutes to 
read.  
Likert scales  After dosing with the study drug, subjects will assess their preference of the study medication by 
answering the statements "I like the taste of the medication” and “The medication is 
acceptable”— using a five-level Likert scale as below:  
 Strongly disagree 
 Disagree 
 Neither agree nor disagree 
 Agree 
 Strongly agree 
 
Drug likability Subjects will also respond to open ended quest ions regarding their experience. Additional 
comments about aftertaste, smell, di ssolve time, etc. will be aske d as Yes/No questions with Yes 
responses prompting an explanation field.     
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 37 of 59 
 12.2 Pharmacokinetics 
Blood samples (4 ml) will be collected per Table 3-1  Schedule of Events. A sample may not be 
collected if the physician indicates in the source documents that th e patient is in a mental state 
that is not conducive to PK sample collection.  
For each subject, up to 3 blood samples (12 mL of blood) will be collected during the study for 
PK analysis. In addition, approximately 30 mL  of blood will be collected at screening, 
approximately 15 mL of blood will be collected at Day 3 Discharge, and approximately 15 mL 
of blood will be collected at Day 7(+2) for clin ical laboratory testing. The total volume of blood 
collected during the study is expected to be approximately 72 mL. Wh enever possible for all 
SAEs a blood sample for PK analysis will be dr awn to evaluate a poten tial relationship with 
exposure.  
Sample Collection & Processing 
Details of the sample process will  be provided in a PK sample manua l, but it is envisioned to be 
the following process: 
 Blood samples will be collected in 4 mL vacutainer tubes containing K 2EDTA.  
 The time and date of the collection of each blood sample will be recorded. 
 After the blood sample has been drawn into th e vacutainer tube, it wi ll be gently inverted 
at least eight (8) times, permitting the blood spec imen to mix with th e anticoagulant and 
avoid clotting of the sample. 
 Keep the tubes on ice until the blood samples can be cen trifuged. Centrifuge blood 
samples at approximately 1500g for 15 minutes at approximately 4°C. 
 Labels will contain the fo llowing information: study numbe r, subject number, study day, 
time point of sample collect ion (e.g., 2 hours post-dose), and aliquot/matrix (e.g., plasma 
primary aliquot or plasma secondary aliquo t). Harvested plasma samples will be quick 
frozen over dry ice immediately. 
 The time elapsed from collection of the blood sample to completion of centrifugation 
should be no more than 60 minutes. 
Sample Storage Plasma samples will be placed in  a storage freezer at -70°C (± 12°C) or on dry ice within 120 
minutes of the blood collection. Samples should be placed in a  - 60°C to - 80°C freezer until 
shipment.  20°C freezers can also be used for a short period of time (m aximum one month) until 
they are shipped to the bioanalytical laboratory. 
Sample Shipment 
 Prior to shipment, the samples will be appr opriately packed into a Styrofoam cooler 
containing dry ice. 
 Sufficient dry ice will be added to ensure that  the samples will remain frozen for at least 
24 hours for local shipments and for at least 72 hours for re mote shipments. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 38 of 59 
  Samples will be shipped in two aliquots. The second set will be shi pped once the status of 
the first set has been verified.  
 The site staff will maintain an inventory of the samples that are to be shipped to the 
bioanalytical laboratory, incl uding the name of the study dr ug, protocol number, and the 
subject numbers and samples included in th e shipment.  A copy of  the inventory will 
accompany the frozen PK samples. 
 The samples will be tracked to ensure arrival in a safe and timely manner. 
 Samples will be shipped to: 
Northeast Bioanalytical Laboratories LLC 
925 Sherman Ave 
Hamden, CT 06514 
Tel: 203-361-3768  
Cell: 203-606-8840 
Analytical Procedures 
12.2.1.1 Bioanalytical Sample Analyses 
A validated LC/MS/MS procedure will be used  to measure plasma concentrations of 
dexmedetomidine (BXCL501). Samp les from subjects who have at  least one post-dose sample 
will be analyzed. 
Analytical results will be presented in tabular form in the final report and chromatographic and 
derived data will also be provided. Additionally, accuracy, precision, and lin earity data for each 
standard curve and all quality control samples will be presented. Representative chromatograms 
and standard curve graphs will be included. A bioanalytical sample analysis report with quality 
assurance statement will be included  in the final clinical study re port (CSR). Copies of serially 
selected sample chromatograms for 20% of all samples will be included in the final report. 
12.2.1.2 Bioanalytical Methodology 
The bioanalytical method, assay validation, and bioanalytical report for this study will be 
provided by the bioanalytical invest igator.  Full validation of a se nsitive assay for the appropriate 
analyte in biological fluid, including precision, ac curacy, reproducibility, and selectivity will be 
included in the final report.  The bioanalytical re port will include the stability of the frozen 
samples, limit of quantitation, recovery, and a summary of the standard curves. 
12.3 Safety 
Safety will be assessed during the study by the monitoring and recordi ng of AEs, clinical 
laboratory test results (hematol ogy, biochemistry, and urinalysis ), vital sign measurements 
(systolic and diastolic blood pre ssures, heart rate measured as  pulse, respiratory rate, and 
temperature), ECG, and physic al examination findings. 
An independent data safety monitoring board (DSM B) will be chartered to review all SAEs and 
AE reports while the study remains blinded to the sponsor. The DSMB will meet regularly to 
evaluate the safety data. Should a known safety  issue be identified (e .g. a high incidence of 
severe hypotension or bradycardia in the activ e 180µg dose arm or the 120µg arm), the DSMB 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 39 of 59 
 will notify the sponsor. Should this occur, sponsor  will notify FDA, and sponsor may choose to 
continue dosing the patie nts at a lower dose. 
 
Adverse Events 12.3.1.1 Adverse Event Definitions 
An AE is defined as any untoward medical occu rrence in a subject or clinical investigation 
patient administered a pharmaceutical product that does not necessarily have a causal 
relationship with the product.  An AE can th erefore be any unfavorable and unintended sign 
(including a new, clinically important abnormal laboratory finding), symptom, or disease 
temporally associated with the product, whet her or not it is re lated to the product. 
Preexisting diseases or conditions will not be cons idered AEs unless there is an increase in the 
frequency or severity, or a change in the qualit y, of the disease or condition.  Worsening of a 
preexisting condition is considered an AE. 
An expected AE is one for which the nature or severity is consistent with the known AE profile 
of the product.  For an investigational drug, the known information is contained in the 
investigator brochure.  For a marketed drug, th e known information is in the current package 
insert. An unexpected AE is one for which the specificity or severity is not cons istent with the current 
investigator brochure or packag e insert.  For example, hepati c necrosis would be unexpected 
(greater severity) if the inves tigator brochure or package insert  only listed elevated hepatic 
enzymes or hepatitis.  Likewise, cerebral th romboembolism and cerebra l vasculitis would be 
unexpected (greater specificity) if  the investigator brochure or pack age insert only listed cerebral 
vascular accidents. Furthermore, reports that add significant info rmation on specificity or severity of a known, 
already documented advers e reaction constitute unexpected AEs.   Examples include acute renal 
failure as an expected adverse reaction with a subsequent new occurrence of interstitial nephritis 
and hepatitis with a first occu rrence of fulminate hepatitis. 
A serious AE (SAE) is any untoward me dical occurrence that at any dose: 
 Results in death 
 Is life threatening 
 Requires inpatient hospitalization or prolongation of exis ting hospitalization 
 Results in persistent or significant disability or incapacity 
 Is a congenital anomaly 
 Is an important medical event 
Medical and scientific judgment should be used in  deciding whether it is appropriate to consider 
other situations serious, such as important medical events that may not be immediately life 
threatening or result in death or hospitalization but may jeopardi ze the subject or may require 
intervention to prevent another of  the outcomes listed in the defi nition previously.  Examples of 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 40 of 59 
 such medical events include allergic bronchos pasm requiring intensive treatment in an 
emergency room or at home, bl ood dyscrasias or convulsions th at do not result in inpatient 
hospitalization, or the development of drug dependency or drug abuse. 
An elective hospital admission to treat a condition present before  exposure to the study drug or a 
hospital admission for a diagnostic evaluation of an AE does not qua lify the conditio n or event as 
an SAE.  A newly diagnosed pregnancy in a subject who has received a study drug is not 
considered an SAE unless it is suspected that the study drug interacted with a contraceptive 
method and led to the pregnancy; however, the medical monitor should be made aware of a 
newly diagnosed pregnancy as s oon as possible after site notific ation.  A congenital anomaly in 
an infant born to a mother who was exposed to the study drug during pregnancy is an SAE. 
12.3.1.2 Eliciting and Documenting Adverse Events 
The investigator is responsible for ensuring that all AEs and SAEs  are recorded in the CRF and 
reported to the medical monitor.  Adverse even ts will be collected from the time of consent 
through the Day 7 (End of Study) or Early Discontinuation visit. 
At each visit, subjects will be asked for any medi cally related changes in their well-being.  They 
will also be asked if they have had any accidents, used any new medications, or changed 
concomitant medication regimens  (both prescription and over-th e-counter medications).  In 
addition to subject observations, AEs will be documented from any data collected on the AE page of the CRF (e.g., clinical  laboratory values, physical examination findings, and ECG 
changes) or other documents that are relevant to subject safety. 
12.3.1.3 Reporting Adverse Events 
All AEs reported or observed during the study will be recorded on the AE page of the CRF.  Information to be collected in cludes drug treatment, type of event, time of onset, dose, 
investigator-specified assessment of severity a nd relationship to study drug , time of resolution of 
the event, seriousness, as well as any required treatment or evaluations , and outcome.  Adverse 
events resulting from concurrent illnesses, reac tions to concurrent illnesses, reactions to 
concurrent medications, or progression of disease st ates must also be reported.  All AEs will be 
followed to adequate resolution.  The latest vers ion of the Med DRA will be used to code all 
AEs. 
Any medical condition that is present at the t ime that the subject is  screened but does not 
deteriorate should not be reported as an AE.  However, if it dete riorates at any time during the 
study, it should be recorded as an AE. The investigator or designee must report a ny AE that meets the criteria for an SAE 
(Section 12.3.1.1) to the medical monitor within 24 hours of firs t becoming aware of the event 
by telephone.  At the time of first notification, th e investigator or desi gnee should provide at a 
minimum the following information if available: 
 Investigator information (name, phone, fax, e-mail) 
 Protocol number 
 Subject’s study identifi cation and initials 
 Subject’s date of birth 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 41 of 59 
  Date of dose of study drug 
 Time and date of occurrence of the event 
 A brief description of the event, ou tcome to date, and any actions taken 
Within 24 hours of the initial not ification, the inve stigator must e-mail a written SAE report form 
to the medical monitor/Safety team.  Any missing  or additional relevant  information about the 
SAE should be provided in a written follow-up SAE report form.  The investigator should also 
ensure that any additional info rmation requested about  the event (e.g., hospita l reports, autopsy 
reports) is provided as so on as it is available. 
The investigator is required to comply with applicable regulations (i ncluding local laws and 
guidance) regarding the notification of the institutional review board (IRB). 
The following contact information is to be used for SAE reporting: 
 
BioXcel Therapeutics, Inc. SAE mailbox: Sa fety@bioxceltherapeutics.com and Cognitive 
Research Corporation: ekemper@cogres.com 
12.3.1.3.1 Assessment of Severity 
The severity or intensity of an AE refers to the extent to which it affects the subject’s daily 
activities.  Severity will be rated as mild, moderate, or seve re using the following criteria: 
Mild: Is usually transient and ma y require only minimal treatment or 
therapeutic interventi on.  The event does not generally interfere 
with usual activities of daily living. 
Moderate: Is usually alleviated w ith additional specific therapeutic 
intervention.  The event interferes with usual activities of daily 
living, causing discomfort  but poses no signifi cant or permanent 
risk of harm to the subject. 
Severe: Interrupts usual activities of  daily living, significantly affects 
clinical status, or may require intensive therapeutic intervention 
Changes in the severity of an AE should be doc umented to allow assessme nt of the duration of 
the event at each level of intensity  to be performed.  Adverse events  characterized as intermittent 
require documentation of onset and duration of each episode. 
12.3.1.3.2 Assessment of Relationship 
The investigator’s assessment of  an AE’s relationship to study drug is part of the documentation 
process but is not a factor in determining what is  or is not reported in the study.  If there is any 
doubt as to whether a clinical observation is an AE, the event should be reported. 
The relationship or association of the study drug  in causing or contributing to the AE will be 
characterized using the followi ng classification and criteria: 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 42 of 59 
 Not related: An AE with sufficient evid ence to accept that there is no causal 
relationship to administration of study drug (e.g., no temporal 
relationship because the study drug was administered after the 
onset of the event, an inves tigation shows that study drug was 
not administered, anot her cause was proven.) 
Unlikely/Remotely related: An AE, including a clinical labor atory test abnormality, with a 
temporal relationship to adminis tration of study drug that makes 
a causal relationship improbable and in which other drugs, 
events, or underlying disease pr ovide plausible explanations. 
Possibly related: An AE with a reason able time sequence to administration of 
study drug but that could also be explained by concurrent 
disease or other drugs or events.  Information on drug 
withdrawal may be lacking or unclear. 
Probably related: An AE with a r easonable time tem poral sequence from 
administration of the study drug; or the AE follows a known pattern of or response to the study drug; or an alternative 
explanation (e.g. concomitant di sease, environment factors, 
and/or concomitant medications) is less likely than attribution to the study drug; or the AE diminishes or disappears upon cessation of study drug.  
Definitely Related: An AE occurring in a plausible time relationship to 
administration of study drug and that cannot be explained by a concurrent disease or other drugs  or events.  The response to 
withdrawal of the drug (dechalle nge) is clinically reasonable. 
12.3.1.3.3 Definition of Adverse Event Outcome at the Time of Last Observation 
The AE outcome at the time of la st observation will be classified as “resolved,” “resolved with 
sequelae,” “ongoing,” “death,” “other,” or “unknown”. 
“Death” should only be selected as an outcome when the AE resu lted in death.  If more than 
1 AE is possibly related to the subject’s death, th e outcome of death should  be indicated for each 
such AE.  Although “death” is usually an even t outcome, events such as sudden death or 
unexplained death should be reported as SAEs. 
12.3.1.4 Follow-up of Adverse Events 
Any AE will be followed (up to a maximum of  30 days after dosing with study drug) to a 
satisfactory resolution or until the investigator de ems the event to be chronic or not clinically 
significant or the subject to be stable.  All findin gs relevant to the final outcome of an AE must 
be reported in the subject’s medical reco rd and recorded on the appropriate CRF. 
C-SSRS 
The Columbia Suicide Severity Rating Scale (C -SSRS) (Oquendo, 2003) is  a suicidal ideation 
rating scale. The scale identifies behaviors and thoughts that are asso ciated with an increased risk 
of suicidal actions in the future. The C-SSRS Baseline/Screening version will be conducted at 
Screening. The C-SSRS Since Last Visit ve rsion will be conducted 24 hours post dosing. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 43 of 59 
 Laboratory Safety Assessments 
Samples for the following laboratory tests will be collected at the time points specified in the 
Schedule of Events ( Table 3.1 ). 
Local Labs (Screening only: To de termine subject eligibility): 
Hematology: Consists of complete blood count (hemoglob in, hematocrit, 
white blood cell count with di fferential, red blood cell 
count, and platelet count) 
Serum chemistry: Includes blood urea ni trogen, creatinine, total bilirubin, 
alkaline phosphatase, aspartat e aminotransferase (serum 
glutamic-oxaloacetic transaminase), alanine 
aminotransferase (serum glut amic pyruvic transaminase), 
glucose, albumin, and total protein 
Urinalysis: Includes pH, specific grav ity, protein, glucose, ketones, 
bilirubin, blood, nitrites, leukocytes, urobilinogen, 
microscopic urine analysis if dipstick positive 
Urine pregnancy test: Conducted for females of childbearing potential only (local 
only) 
Urine Drug Screen: Cocaine, amphetami ne, phencyclidine, benzodiazepines, 
marijuana. (Note; marijuana positive is allowed provided 
subject is not moderately  to severely dependent, 
benzodiazepine positive are allowed if prescribed)  
Alcohol breathalyzer: Only  conducted at screening 
Central Labs (Screening, Day 3 and Day 7): 
Hematology: Consists of complete blood count (hemoglob in, hematocrit, 
white blood cell count with diffe rential, red blood cell count, 
and platelet count) 
Serum chemistry: Includes blood urea nitrogen, creatinine, total bilirubin, alkaline 
phosphatase, aspartate aminotra nsferase (serum glutamic-
oxaloacetic transaminase), alan ine aminotransferase (serum 
glutamic pyruvic tr ansaminase), glucose,  albumin, and total 
protein 
Urinalysis: Includes pH, specific grav ity, protein, glucose, ketones, 
bilirubin, blood, nitrites, leukoc ytes, urobilinogen, microscopic 
urine analysis if dipstick positive 
 
Vital Signs 
Resting vital signs, including systolic, diastolic  blood pressure, and heart rate (measured as 
pulse) will be measured after the subject has been  in a recumbent position for at least 5 minutes 
at the time points specified in the schedule of events ( Table 3.1 ).  Measurements should be made 
at least 1 minute apart using the same arm at each visit. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 44 of 59 
 At indicated timepoints orthostatic measurement of systolic , diastolic blood pressure, and heart 
rate will be measured after the s ubject has been standing for a tota l 1, 3 and 5 minutes at the time 
points specified in the schedule of events ( Table 3.1 ). Temperature and respiratory rate will be 
recorded when orthostatic measurement is indi cated in the schedule of events and are not 
required to be measured at re sting vital sign timepoints.  
If the first measurement of vita l signs (SBP, DBP, and pulse) shows the following, vital signs 
will be measured again in triplicate (same arm, separated by at least 1 minute) for; 
Systolic Blood Pressure <90 mmHg 
Diastolic Blood Pressure <60 mmHg Pulse < 60 bpm 
 Electrocardiogram A 12-lead ECG with rhythm strip will be perf ormed at Screening, Pre-dose, 2, and 24 hours post 
dose and 2 hours post any re-dose. Date and time of ECG, ventricular heart rate (beats/minute), 
P-R Interval, QRS Duration, QT Interval (mse c) will be collected. QTcF (msec) will be 
calculated. 
Pulse Oximetry 
Pulse oximetry will be performed  at pre-dose and repeated 30  mins, 1, 2, 4, and 8 hours post 
dose. (Table 3.1) 
 Physical Examination 
A standard physical examination will be perf ormed at Screening and 24 hours post dose.  The 
examination will include assessment of skin, hea d, ears, eyes, nose, throat, neck, thyroid, lungs, 
heart, cardiovascular, abdomen, lymph nodes, and musculoskeletal system/extremitie s.  Interim 
physical examinations will be perf ormed at the investigator’s discretion if necessary, to evaluate 
AEs or clinical labor atory abnormalities. 
Height and weight will be measured at Screening and weight will be measured again at the Day 
of discharge. BMI will be calculated and recorded. 
 Concomitant Medications 
Concomitant medications will be reviewed and documented  during each study visit. 
Likert scales After dosing with the study drug, subjects will assess their preference of the study medication by 
answering the statements "I like the taste of the medication” and “The medication is 
acceptable”— using a five-level Likert scale as below:  
 Strongly disagree 
 Disagree 
 Neither agree nor disagree 
 Agree 
 Strongly agree 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 45 of 59 
 Drug likability 
Subjects will also respond to open ended quest ions regarding their experience. Additional 
comments about aftertaste, smell, di ssolve time, etc. will be aske d as Yes/No questions with Yes 
responses prompting an explanation field.  
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 46 of 59 
 13. STATISTICAL METHODS 
13.1 General Considerations 
A Statistical Analysis Plan (SAP) that describes the deta ils of the analyses to be conducted will 
be finalized before database lock. 
13.2 Analysis Populations 
The following analysis popul ations are planned:  
 Safety Population: All subj ects who receive study drug. 
 Intent to treat (ITT) Populat ion: All subjects in the Safe ty Population who have a PEC 
Score post-dose; 
 Per Protocol (PP) Population: All subjects in  the ITT Population with no major protocol 
deviations; 
13.3 Statistical Analyses 
Continuous variables will be su mmarized by treatment using desc riptive statistics (n, mean, 
median, standard deviation, minimum, and maximu m). For categorical vari ables, frequencies and 
percentages will be presented by treatment. Baseline  is defined as the last observation prior to 
initiation of study medication. Miss ing data will be imputed usi ng multiple imputation. As the 
prior studies had little missing data, it is anticipa ted that methods for mono tone missing data will 
be used with values imputed as needed. Effic acy analyses and summaries will be presented for 
both the ITT Population and the PP Population, with  the former being primary. Details of the 
statistical analyses will be provided in the Statis tical Analysis Plan whic h will be finalized prior 
to database lock. Subject Disposition and Dem ographic Characteristics 
Subject disposition will include the number of subjects who enroll in the study and the number 
and percentage of subjects included in each analysis population by treatment. The frequency and 
percentage of subjects who withdraw or disc ontinue from the study, along  with the reason for 
withdrawal or discontinuation, wi ll be summarized by treatment. 
Demographics and baseline characteristics, in cluding age, sex, race, weight, height, and body 
mass index (BMI), will be summarized by treatment for the Safety Population. 
Efficacy Analyses 
The primary efficacy endpoint of the study will be the absolute change from baseline in the PEC 
total score at 120 min. The intent to treat populati on will be analyzed and consist of all patients 
who take any study medication and who had both baseline and at leas t 1 efficacy assessment 
after dosing. Observations record ed after use of rescue medication will be censored (considered 
missing). The null and altern ative hypotheses to be te sted are stated as H
01: ∆BXCL501_180  = ∆PBO and 
HA1: ∆BXCL501_180  ≠ ∆PBO and H 02: ∆BXCL501_120  = ∆PBO and H A2: ∆BXCL501_120  ≠ ∆PBO, where ∆BXCL501_180  
denotes the change from base line in the PEC at 2 hours pos t-dose in the BXCL501 180 µg 
group, ∆BXCL501_180  denotes the change from baseline in  the PEC at 2 hours post-dose in the 
BXCL501 180 µg group, ∆BXCL501_120  denotes the change from ba seline in the PEC at 2 hours 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 47 of 59 
 post-dose in the BXCL501 120 µg group, and ∆PBO denotes the change from baseline in the PEC 
at 2 hours post-dose in the placebo group. These hypotheses, H 01 and H 02, will be tested using a 
mixed model repeated measures (MMRM) model. To account for the testing of two hypotheses, 
the two-sided significance level for each test will be determined using the Bonferroni correction 
and set at 0.025. The outcome variable for the MMRM will be the change from baseline in the 
PEC score at 10, 20, 30, 45, 60, 90, and 120 minutes and the following set of covariates: 
treatment group, baseline PEC, visit, baseline PEC by visit interaction term, and treatment group 
by visit interaction term. The test  of the null hypothesis is obtain ed from a least squares mean 
analysis. A sensitivity analysis will be conducted to assess the impact of any missing data. Control-based, multiple imputation will be used  to impute missing values based on the placebo 
group experience, with details of the sens itivity analysis provided in the SAP. 
The key secondary endpoints will be evalua ted using the fixed-se quence method with the 
endpoints ordered in a hierarchy within each dosing group comparison with testing stopping 
once a significance leve l is greater than 0.025. The key seco ndary endpoints are as follows: 
1. Change from baseline in the PEC score at 90 minutes. 
2. Change from baseline in the PEC score at 60 minutes. 
3. Change from baseline in the PEC score at 45 minutes. 
4. Change from baseline in the PEC score at 30 minutes. 
5. Change from baseline in the PEC score at 20 minutes. 
6. Change from baseline in the PEC score at 10 minutes.  
 
Other exploratory endpoints include: 
1. Overall clinical improvement  after drug administration as  measured by the Clinical 
Global Impression – Improveme nt Scale (CGI-I) score 
2. Agitation-Calmness Evaluation Scale (ACES) scores at 2, 4 and 8 hrs after dose 
administration.  
3. Change from baseline in total PEC score over time measured from 10 min through 24 
hrs after dosing.  
4. PEC Responders and CGI-I Responders at 2 hours following dose of BXCL501, 
compared with placebo:   
a. PEC responders will be defined as those who achieve at least a 40% reduction in 
PEC total score from baseline at or before 2 hours post-dose. 
b. CGI-I responders will be defined as subj ects with a score of 1 or 2 on the CGI-I 
scale (the CGI-I non-responders will be define d as subjects with scores from 3 to 
7 at 2 hours).   
5. Time to rescue medication dur ing the entire 24 hrs Post-treatment Evaluation Period for 
subjects receiving BXCL501 compared to placebo. 
6. Number of subjects per treatment group w ho received rescue me dication by 4 hrs and 
within 24 hrs after dosing.  
7. Duration of calming effect as described by the change from baseline in PEC total score 
at 4, 6, 8 and 24 hrs after dosing. 
8. Determine the safety profile of BXCL501 as  measured by vital signs and treatment-
emergent adverse event reports and vital signs. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 48 of 59 
 9. Describe the overall tolerability in term s of adverse event re ports and local site 
(oral/sublingual) tolerability of oral film. 
10. Descriptive pharmacokinetics of BX CL501 in the patient population. 
11. Determine patient acceptability, taste and likability of study medication using Likert 
scales to capture subject’ s acceptability, opinion on taste and questions regarding 
likability. 
12. Characterize the patient population utiliz ing the Young Mania Rating Scale (YMRS). 
The exploratory outcomes will be analyzed us ing a variety of techniques depending on the 
outcome and including two-sample t-tests, Fisher’s exact test, Kaplan-Meier curves for time-to-
event outcomes and descriptive methods such as box plots, frequency distributions and shift 
tables. All significance levels will be reported as nominal levels. 
Safety Analyses 
All safety analyses will be perfo rmed using the Safety Populati on. All subjects who received at 
least one dose of study drug will be include d in the population for safety analysis. 
Adverse events (AEs) will be characterized by ty pe, severity, seriousness, and relationship to 
treatment. Adverse events will be coded by preferred term and system organ class using 
MedDRA version 20.0. Incidence of  AEs will be summarized by trea tment overall, by severity, 
and by relationship to study drug.  Serious AEs and AEs leading to discontinuation of study drug 
will also be presented. 
Vital sign, ECG with rhythm st rip, and clinical laboratory re sults will be summarized by 
treatment. Physical examination findings will be listed. 
Pharmacokinetic Analyses 
Plasma concentrations and concentration-time  data for dexmedetomidine will be used to 
calculate PK parameters; these data and results will be reported separately. Details regarding the 
analyses of PK data will be described in a separate PK SAP. The se parate SAP for the PK 
analyses will be prepared and finalized prio r to database lock. Da ta from subjects who 
participated in the study will be included in the pharmacokinetic analysis. Subjects with missing 
sample concentrations will be included in the pharmacokinetic analyses provided their pharmacokinetic parameters can be adequately  characterized based upon the remaining data. 
Deviation from procedures describe d in this protocol that impact  the quality of data required to 
meet the objectives of the st udy will be documented and ma y result in exclusion of 
pharmacokinetic data from the anal yses for a particular subject. Th is includes any deviations or 
events that would invalidate the evaluation of th e pharmacokinetics. Exampl es of deviations and 
events which could result in excl usion of pharmacokinetic data from the analyses include emesis 
after dosing (within the predetermined time), samp le processing or assay errors that lead to 
inaccurate bioanalytical results. Other deviations  or events, which do not disqualify data from 
analyses, may require minor adjustments to calcula tions. If these occur, data analyses will be 
adjusted and documented accordingly such that c onclusions are not biased. An example of such 
an event includes, but is not li mited to, minor deviations between the actual and scheduled time 
of sample collection. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 49 of 59 
 All pharmacokinetic parameters will be calcu lated using non-compartme ntal analysis using 
WinNonlin Version 5.2 or higher. Actual sampli ng times will be used in all pharmacokinetic 
analyses. Per protocol times will be used to calculate mean plas ma concentrations for graphical 
displays. 
Other PK analyses may be performed as appropriate . 
13.4 Sample Size Determination 
The estimated sample size was estimated using information from the Phase 2  study regarding 
the standard deviation of the ch ange from baseline in PEC score and the expected magnitude of 
this difference. Under the assumptions of a tw o-sided significance leve l of 0.025, a two-sample t-
test, a randomization ratio of 1:1, an assumed power of 0.90, and standard deviations of 4.0, 4.2, 
4.4, and 4.6. The estimated sample size per group is provided in Table 13.1 below. Table 13.1 2 
provides the estimated sample size per group for a power of  0.85. The observed difference 
between the BXCL501 and placebo groups in the 180µg group was 0.7, 3.5, 5.0, 6.0, and 6.2 at 
30, 45, 60, 90, and 120 minutes, respectively. With a sample size of approxima tely 375 subjects 
(125/group) the study is well power ed to detect differences at 45 minutes or later.  
A blinded sample size recalculation will take pla ce when approximately 50% of the information 
is available. The pooled standard deviation of the change from ba seline in PEC total score will 
be computed at each time point. The sample size w ill then be recalculated with the potential to 
adjust the sample size accordingly. 
Table 13.1: Estimated Sample Size group for power of 0.90 
Estimated sample size/group for power of 0.90, a two-sided significance level of 0.025,  varying 
mean difference in change from baseline in PEC score, and standard deviations of the change 
from baseline in PEC score.  
     Standard deviatio n 
Mean difference  4.0  4.2  4.4  4.6 
 2.0  101  111  122  133 
 1.9  112  123  135  147 
 1.8  124  137  150  164  1.7  139  153  168  184 
     
Table 13.2: Estimated Sample Size group for power of 0.85 
Estimated sample size/group for power of 0.85, a two-sided significance level of 0.025, varying 
mean difference in change from baseline in PEC score, and standard deviations of the change 
from baseline in PEC score. 
     Standard deviatio n 
Mean difference  4.0  4.2  4.4  4.6 
 2.0   88    97  106  115 
 1.9   97  107  117  128 
 1.8  108  119  130  142  1.7  121  133  146  159 
     
 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 50 of 59 
 14. STUDY CONDUCT 
Steps to ensure the accuracy and reliability of data  include the selection of qualified investigators 
and appropriate study sites, review of protocol procedures with the investigator and associated 
personnel prior to the study, period ic monitoring visits, and strict data mana gement procedures. 
14.1 Sponsor and Investigator Responsibilities 
Sponsor Responsibilities 
The sponsor is obligated to conduc t the study in accordance with st rict ethical principles.  The 
sponsor reserves the right to w ithdraw a subject from the study, to terminate participation of a 
study site at any time, or to discontinue the study. 
The sponsor agrees to provide th e investigator with sufficient material and support to permit the 
investigator to conduct the study according to th e study protocol. 
Investigator Responsibilities By signing the Investigator’s Agreement, the inves tigator indicates that he  or she has carefully 
read the protocol, fully understands the requirements, and ag rees to conduct the study in 
accordance with the procedures and requirements described in this protocol. The investigator also agrees to conduct this study in accordance with all laws, regulations, and 
guidelines of the pertinent regulatory authoriti es, including and in accordance with the April 
1996 International Conference on Ha rmonisation (ICH) Guidance for Industry E6 Good Clinical 
Practice (GCP) and in agreement with the 1996 Vers ion of the Declaration of Helsinki.  While 
delegation of certain aspects of the study to sub-investigat ors and study coor dinators is 
appropriate, the investigator wi ll remain personally accountabl e for closely overseeing the study 
and for ensuring compliance with th e protocol and all applicable regulations and guidelines.  The 
investigator is responsible for maintaining a list of all persons  that have been delegated study-
related responsibilities (e.g., sub-investigators and study coordina tors) and his or her specific 
study-related duties. 
Investigators should ensure that all persons  who have been delegated study-related 
responsibilities are adeq uately qualified and informed about  the protocol, st udy drugs, and their 
specific duties within the context of the study.  Investigators are responsible for providing the 
sponsor with documentation of the qualificatio ns, GCP training, and research experience for 
themselves and their staff as required by the sponsor and the re levant governi ng authorities. 
To ensure compliance with the gu idelines, the study will be audited by an independent person.  
The investigator agrees, by written consent to this protocol, to cooperate fully with compliance 
checks by allowing access to all study doc umentation by authorized individuals. 
14.2 Site Initiation 
Study personnel may not screen or enroll subjects into the study until after receiving notification 
from the sponsor or its designee that the study can be initiated at the stud y site.  The study site 
will not be authorized for study initiation until: 
1. The study site has received the appropriate IRB approval for the protocol and the appropriate 
informed consent. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 51 of 59 
 2. All GCP documents have been submitted to a nd approved by the sponsor or its designee. 
3. The study site has a Clinical Trial Agreement in place. 
4. Study site personnel, including th e investigator, have particip ated in a study initiation 
meeting. 
14.3 Study Documents 
All documentation and material provided by the s ponsor for this study are to be retained in a 
secure location and treated as confidential mate rial. Confidentiality of records identifying the 
subject will be maintained. The Food and Drug Ad ministration may inspect the records at any 
time. 
Good Clinical Practice Documents 
The GCP documents are listed below. 
 Signed original protocol (i.e ., Investigator’s Agreement) 
 Curricula vitae of all inves tigators and sub-investigators 
 Name and address of  the laboratories 
 List of laboratory refere nce ranges, and if availa ble, a quality certificate 
 FDA Form 1572 
 Any other relevant GCP documents 
The GCP documents must be received from the investigator and reviewed and approved by the 
sponsor or designee before the study site can initiate the study and before the sponsor will 
authorize shipment of study drug to  the study site.  Copies of the investigator’s GCP documents 
must be retained at the study s ite in a secure locati on.  Additional documents, including a copy of 
the protocol and applicable am endment(s), the study drug, CRF co mpletion guidelines, copies of 
regulatory references, copies of IRB correspondence, and st udy drug accountability records 
should also be retained as part of the investigator’s GCP documen ts.  It is the investigator’s 
responsibility to ensure that copies of all required GCP documents are organized, current, and 
available for inspection. 
Case Report Forms 
By signing the Investigator’s Agreement, the investigator agrees to maintain accurate CRFs and 
source documentation as part of th e case histories for all subjects who sign an informed consent 
form. 
Case report forms are consider ed confidential documents and should be handled and stored 
accordingly.  The sponsor or its designee will provide the necessary training on the use of the 
specific CRF system used during the study to ensure that the study information is captured 
accurately and appropriately. 
To ensure data accuracy, CRF data for individua l subject visits should be completed as soon as 
possible after the visit.  All requested information must be entered in the CRF according to the 
completion guidelines provided by the sponsor or its designee. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 52 of 59 
 The CRFs may be signed by the investigator or a sub-investigator.  These signatures serve to 
attest that the information containe d in the CRF is accurate and true. 
Source Documents 
All information recorded in the CRF must be supported by corresponding source documentation.  
Examples of acceptable source documentation include , but are not limited to, hospital records, 
clinic and office charts, laborat ory notes, and recorded data from automated instruments, 
memoranda, and pharmacy dispensing records. 
During the study, select CRF data may be used as original data collection tools as long as a 
description of this docume ntation process is maintained in the investigato r’s study files.  Before 
the study starts, a list identifying any data to be  recorded directly on the CRFs (i.e., no prior 
written or electronic record of data) and cons idered to be source data will be provided. 
Clinical laboratory data required by the protocol will be electronically transferred from the 
central laboratory to the sponsor or its designee. A paper copy of the laboratory results will be 
provided to the study site and should be re tained with each subject’s source data. 
14.4 Data Quality Control 
The sponsor and its designees will perform qua lity control checks on this clinical study. 
Monitoring Procedures 
The sponsor or designee will conduc t site visits to monitor the study and ensure compliance with 
the protocol, GCP, and applicable regulations an d guidelines.  The assigned clinical research 
associate (CRA) will visit the investigator and study site at periodic intervals and maintain 
periodic communicatio n.  The investigator agrees to allow the CRA and other authorized sponsor 
personnel access.  The CRA will maintain cu rrent personal knowledge of the study through 
observation, review of study records and source documentation, and discu ssion of the conduct of 
the study with the investigator and sta ff. While on site, the CRA will review: 
 Regulatory documents, directly comparing entries in the CRF with the source documents 
 Consenting procedures 
 AE procedures 
 Storage and accountability of study drug and study materials 
The CRA will ask for clarification or correction of  any noted inconsistencies.  Procedures for 
correcting CRFs are described in  the study manual.  As represen tatives of the sponsor, CRAs are 
responsible for notifying pr oject management of any not ed protocol deviations. 
By signing the Investigator’s Agreement, the investigator agrees to meet with the CRA during 
study site visits; to ensure that study staff is available to the CR A as needed; to provide the CRA 
access to all study documentation, to the clinical supplies dispensing and storage area; and to assist the monitors in their activities, if requeste d.  Further, the investigator agrees to allow the 
sponsor or designee auditors or inspectors from regulatory agencies to review records and to 
assist the inspectors in their duties, if requested. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 53 of 59 
 Data Management 
The sponsor or designee will be re sponsible for activities associat ed with the data management 
of this study.  The standard procedures for ha ndling and processing records will be followed per 
GCP and the sponsor’s or Contract Resear ch Organization’s (CRO) standard operating 
procedures.  A comprehensive data management  plan will be developed including a data 
management plan, database contents, annotated CRF, self-evident correction conventions, query 
contacts, and consistency checks. 
Study site personnel will be responsible for providing resolutions to al l data queries.  The 
investigator will be required to document data re view to ensure the accuracy of the corrected 
and/or clarified data.  Procedures for soliciti ng and documenting resoluti on to data queries are 
described in the Data Management Plan. 
Quality Assurance/Audit 
This study may be subject to audit by the sponsor or  designee.  The audits may be undertaken to 
check compliance with GCP guidelines and may include: 
 In-house study file audit 
 Audit of computer data base quality control 
 Audit of clinical re port quality control 
The sponsor or designee may c onduct additional audits on a sele ction of study sites, requiring 
access to subject notes, study documentation, and facilities or laboratories used for the study. 
The study site, facilities, all data (including source data), and documentation will be made 
available for audit by quality assu rance auditors and for IRB or regulatory authorities according 
to GCP guidelines.  The investigat or agrees to cooperate with th e auditor during th e visit and will 
be available to supply the audito r with CRFs or other files necessa ry to conduct that audit.  Any 
findings will be stri ctly confidential. 
If a regulatory authority informs the investigator that it inte nds to conduct an  inspection, the 
investigator shall notify the sponsor immediately. 
14.5 Study Termination 
The study may be terminated at the sponsor’s  discretion at any tim e and for any reason. 
Regular Study Termination 
The end of this study is defined as the date of the last visit of the last subject (last subject out or 
last subject last visit) particip ating in the study.  Within 90 days of the end of the clinical study, 
the sponsor or designee will not ify the IRB and regulatory au thorities about the regular 
termination of the study as required. 
Premature Study Termination 
The study may be terminated prem aturely for any reason and at any time by the sponsor, IRB, 
regulatory authorities, or the c oordinating investigator .  A decision to prem aturely terminate the 
study is binding to all inves tigators of all study sites. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 54 of 59 
 Within 15 days of premature termination of a clinical study, the sponsor  or designee will notify 
the IRB and regulatory authoritie s as required. The sponsor or de signee must clearly explain the 
reasons for premature termination. 
If the study is terminated prematurel y, all investigators must inform  their subjects and take care 
of appropriate follow-up and further treatment of subjects to en sure protection of the subjects’ 
interests.  Study sites may be asked to have all subjects currently pa rticipating in the study 
complete all of the assessments for the Early Termination visit. 
14.6 Study Site Closure 
At the end of the study, all study sites will be clos ed. The sponsor may terminate participation of 
a study site at any time.  Exampl es of conditions that may requ ire premature termination of a 
study site include, but are not  limited to, the following: 
 Noncompliance with the protocol, applicab le regulations and guidelines, or both; 
 Inadequate subject enrollment. 
Record Retention 
The investigator shall retain and preserve one copy of all data generated in the course of the 
study. All records and documents pertaining to the study including, but not limited to those 
defined by GCP as essential will be retained until at least 2 years after the last approval of a 
marketing application in an IC H region and until there are no pe nding or contemplated marketing 
applications in an ICH region or at least 2 year s have elapsed since the formal discontinuation of 
clinical development of the drug. These documents should be retained for a longer  period, however, if required by the applicable 
regulatory requirement(s) or by an agreement with  the Sponsor. It is the responsibility of the 
Sponsor to inform the Investigator/institution when these documents no longer need to be 
retained. To avoid any possible errors, the Investigator will contact  the Sponsor before 
transferring or destroying any study records. Th e Investigator will also promptly notify the 
Sponsor in the event of accidental loss or destruction of any study records. 
At the end of such period, the investigator shall notify the sponsor in writi ng of his or her intent 
to destroy all such material. The sponsor shall have 30 days to respond to the investigator’s 
notice, and the sponsor shall have a further opportun ity to retain such mate rials at the sponsor’s 
expense. After completing the study, the sponsor will be pr ovided with the original CRFs or at least a 
legible copy and retain the documents at l east 5 years after the co mpletion of the study. 
One copy will remain with the investigator.  The investigator shall arrang e for the retention of 
the subject identification codes, subject files, an d other source data until at least 5 years after 
notification of submission of th e final study report to the regulato ry authorities by the sponsor.   
Sample Retention Samples may be used for purposes related to this  research.  The samples will be stored until the 
sponsor has determined that specimens are no longer needed, and the decision has been made 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 55 of 59 
 that none of the samples needs to  be reanalyzed or at the comp letion of the CSR.  In addition, 
identifiable samples can be destroyed at any time at the reque st of the subject. 
14.7 Changes to the Protocol 
This protocol cannot be altered or changed ex cept through a formal prot ocol amendment, which 
requires the written approval by th e sponsor.  The protocol amendment must be signed by the 
investigator and approved by the IRB before it may be implemented.  Protocol amendments will 
be filed with the approp riate regulatory agency. 
14.8 Use of Information 
All information about the study dr ug, the sponsor’s operations, patent applications, formulas, 
manufacturing processes, basic sc ientific data, and formulation information supplied by the 
sponsor or designee to the inves tigator and not previously publish ed, is considered confidential 
and remains the sole property of the sponsor.  Case report forms al so remain the property of the 
sponsor.  The investigator agrees to use this information for purposes of study execution through 
finalization and will not use it for other purposes without th e written consent of the sponsor. 
The information developed in this study will be used by the sponsor in connection with the 
continued development of the study drug and thus may be disclosed as required to other clinical 
investigators or government  regulatory agencies. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 56 of 59 
 15. FINAL CLINICAL STUDY REPORT 
The final study report will be wr itten according to the “Guideline  for Industry (Structure and 
Content of Clinical Study Reports)” from the International Conferen ce on Harmonisation (ICH) 
E3. The final study report will present a narrativ e description of the clinical, analytical, 
pharmacokinetic, and statistical results. Tables a nd figures will be “integrated” into the main 
text, with appendices at the e nd of the report (e.g., the protoc ol, sample CRFs, investigator-
related information, test/reference product in formation, subject data listings).   
The final CSR will be submitted to th e appropriate regulatory authorities. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 57 of 59 
 16. ETHICAL AND LEGAL CONSIDERATIONS 
16.1 Declaration of Helsinki and Good Clinical Practice 
This study will be conducted in compliance with  the November 2016 ICH Guidance for Industry 
E6(R2) GCP and the 1996 Version of  the Declaration of Helsinki. 
16.2 Subject Information and Informed Consent 
A properly constituted, valid IRB must review and approve the protocol, the investigator’s 
informed consent document, and related subject in formation and recruitment materials before the 
start of the study. 
It is the responsibility of the investigator to en sure that informed consent has been obtained from 
the subject before any activity or  procedure is undertaken that is not part of routine care. 
16.3 Approval by Institutional Review Board 
A valid IRB must review and appr ove this protocol before study initiation.  Written notification 
of approval is to be submitted by the investigator to the sponsor  monitor before shipment of 
investigational drug supplies and will include the date of the committee’s approval and the 
chairperson’s signature.  This  written approval must consist of a completed sponsor IRB 
Approval Form or written documentation from the IRB containing th e same information. 
Until written approval by the IRB has been recei ved by the investigator, no subject may undergo 
any procedure solely for determin ing eligibility for this study. 
Protocol amendments must also  be reviewed and approved by the IRB.  Written approval from 
the IRB, or a designee, must be  received by the sponsor before  implementation.  This written 
approval will consist of a completed IRB Approva l form or written documentation from the IRB 
containing the same information. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 58 of 59 
 17. REFERENCES 
 
Alderfer BS, Allen MH. Treatment of Agitation in  Bipolar Disorder Across the Life Cycle. J 
Clin Psychiatry. 2003; 64 (Suppl 4): 3-9. 
Allen MH, Currier GW, Hughes DH, Docherty JP, Carpenter D, Ross R. Treatment of 
Behavioral Emergencies: A Summary  of the Expert Consensus Guid elines. Journal of Psychiatric 
Practice. 2003; 9: 16–38. Allen MH, Feifel D, Lesem MD, Zimbroff DL , Ross R, Munzar P, Spyker DA, Cassella JV. 
Efficacy and Safety of Loxapine  for Inhalation in the Treatment of Agitation in Patients with 
Schizophrenia: A Randomized, Double-Blind, Placebo- Controlled Trial. J Clin Psychiatry. 2011; 
72 (10): 1313-1321. Battaglia J. Pharmacological  Management of Acute Agita tion. Drugs. 2005; 65 (9): 1207-1222. 
Bellnier TJ. Continuum of Care : Stabilizing the Acutely Agitat ed Patient. Am J Health-Syst 
Pharm. 2002; 59 (Suppl 5): S12-8. Berk M, Dodd S. Efficacy of Atypical Antipsych otics in Bipolar Disorder. Drugs 2005; 65 (2): 
257-269. Conn DK, Lieff S. Diagnosing and Managing Deli rium in the Elderly. Can Fam Physician. 2001; 
47: 101-108. 
Currier GW, Trenton A. Pharmacological Treatment of Psychotic Agitation. CNS Drugs. 2002; 
16 (4): 219-228. 
Currier GW, Allen MH, Bunney EB, Daniel DG, Fr ancis A, Jagoda A, Zimbroff D. Standard 
Therapies for Acute Agitation. Journal of Emergency Medicine. 2004; Vol. 27: S9–S12. 
Levin, Harvey S., Vincent M. O'donnell, and Robe rt G. Grossman. "The Galveston Orientation 
and Amnesia Test: A practical scal e to assess cognition after head  injury." Journal of Nervous 
and Mental Disease (1979). 
Lindenmayer JP. The Pathophysiology of Agitatio n. J Clin Psychiatry. 2000; 61 (Suppl 14): 5-
10. 
Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch K, Rizk R, Walker D, Tran P, 
Breier A.
 A Double-Blind, Randomized Comparison of th e Efficacy and Safety of Intramuscular 
Injections of Olanzapine, Lorazepam, or Placebo in Treating Acutely Agitated Patients 
Diagnosed with Bipolar Mania.  Clin Psychopharmacol. 2001; 21: 389–397. 
Meehan KM, Wang H, David SR, Nisivoccia JR, J ones B, Beasley CM Jr, Feldman PD, Mintzer 
JE, Beckett LM, Breier A. Comparison of Rapidl y Acting Intramuscular Ol anzapine, Lorazepam, 
and Placebo: A Double-blind, Randomized Study in Acutely Agitated Patients with Dementia. 
Neuropsychopharmacology. 2002; 26: 494–504. 
BioXcel Therapeutics, Inc. Confidential BXCL501-302 
 
 
Protocol BXCL501-302 – Version 3 31-JAN-2020  Page 59 of 59 
 MHRA. CLH Report: Proposal for Harmonised Cl assification and Labell ing, Substance Name: 
Medetomidine. October 2014. Version 1. 
Oquendo MA, Halberstam B, Mann JJ. Colombia Suicide Severity Rating Scale (C-SSRS) – 
Risk Factors for Suicidal Behavior: The Utility and Limitations of Res earch Instruments, in 
Standardized Evaluation in Clinical Practice. Fi rst MB, editor. American Psychiatric Publishing; 
Washington, DC: 2003: 103-131. 
Osser DN, Sigadel R, Short-Term  Inpatient Pharmacotherapy of Schizophrenia. Harvard Review 
of Psychiatry. May-June 2001;  Volume 9 (Issue 3): 89-104. 
Precedex. US Package Insert. 2016 May. 
Sanford M, Scott LJ. Intramuscu lar Aripiprazole a Review of its Use in the Management of 
Agitation in Schizophrenia and Bipolar I Disorder. CNS Drugs. 2008; 22 (4): 335-352. 